成纤维细胞激活蛋白靶向治疗:[177Lu]FAPI-46与[225Ac]FAPI-46在胰腺癌模型中的比较
该研究在PANC-1胰腺癌异种移植小鼠模型中,用[18F]FAPI-74进行伴随PET显像,并比较β发射体[177Lu]FAPI-46与α发射体[225Ac]FAPI-46的体内分布与治疗效果。两种放射性药物均显示肿瘤抑制效应,[177Lu]FAPI-46起效相对缓慢但作用持续时间长于[225Ac]FAPI-46,提示FAPI放射性配体治疗可用于表达FAP的胰腺癌。
要点
- [177Lu]FAPI-46与[225Ac]FAPI-46在PANC-1模型中均显示肿瘤抑制效应,伴体重轻度下降。
- [177Lu]FAPI-46起效相对慢但疗效持续时间长于[225Ac]FAPI-46。
- [18F]FAPI-74给药1小时后经肾快速清除,肿瘤与肠道高摄取。
核心结论
- 在表达FAP的胰腺癌模型中,[177Lu]FAPI-46与[225Ac]FAPI-46均显示肿瘤抑制效应,提示FAPI放射性配体治疗可能应用于表达FAP的胰腺癌。
- [177Lu]FAPI-46的治疗效应相对缓慢但持续时间长于[225Ac]FAPI-46。
研究设计与样本
- PANC-1胰腺癌异种移植小鼠(n=9)注射[18F]FAPI-74(12.4±1.7 MBq)后1小时行PET扫描作伴随显像。
- 在异种移植模型(总n=12)中评估[177Lu]FAPI-46与[225Ac]FAPI-46的体内分布。
- 疗效评估中[177Lu]FAPI-46剂量分组为3 MBq(n=6)、10 MBq(n=6)、30 MBq(n=6)、对照(n=4)。
- [225Ac]FAPI-46剂量分组为3 kBq(n=3)、10 kBq(n=2)、30 kBq(n=6)、对照(n=7),随访肿瘤大小与体重。
主要发现
- [18F]FAPI-74给药1小时后经肾快速清除,肿瘤与肠道高蓄积。
- [177Lu]FAPI-46与[225Ac]FAPI-46在3小时均经肾快速清除,肿瘤有相对较高蓄积。
- 两种药物均显示肿瘤抑制效应,伴体重轻度下降。
- [177Lu]FAPI-46疗效相对缓慢但持续时间长于[225Ac]FAPI-46。
临床怎么用
- 研究提示FAPI放射性配体治疗在表达FAP的胰腺癌中具有潜在应用价值,但尚属临床前模型结果,需进一步研究确定最佳放射性核素及与直接靶向肿瘤细胞治疗的联合方案。
局限性
- 结论基于PANC-1异种移植小鼠模型,样本量小(如[225Ac]FAPI-46的10 kBq组仅n=2),尚需进一步研究确定半衰期更短的合适核素及联合治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Fibroblast activation protein (FAP), which has high expression in cancer-associated fibroblasts of epithelial cancers, can be used as a theranostic target. Our previous study used 64Cu and 225Ac-labelled FAP inhibitors (FAPI-04) for a FAP-expressing pancreatic cancer xenograft imaging and therapy. However, the optimal therapeutic radionuclide for FAPI needs to be investigated further. In this study, we evaluated the therapeutic effects of beta-emitter (177Lu)-labelled FAPI-46 and alpha-emitter (225Ac)-labelled FAPI-46 in pancreatic cancer models. METHODS: PET scans (1 h post injection) were acquired in PANC-1 xenograft mice (n = 9) after the administration of [18F]FAPI-74 (12.4 ± 1.7 MBq) for the companion imaging. The biodistribution of [177Lu]FAPI-46 and [225Ac]FAPI-46 were evaluated in the xenograft model (total n = 12). For the determination of treatment effects, [177Lu]FAPI-46 and [225Ac]FAPI-46 were injected into PANC-1 xenograft mice at different doses: 3 MBq (n = 6), 10 MBq (n = 6), 30 MBq (n = 6), control (n = 4) for [177Lu]FAPI-46, and 3 kBq (n = 3), 10 kBq (n = 2), 30 kBq (n = 6), control (n = 7) for [225Ac]FAPI-46. Tumour sizes and body weights were followed. RESULTS: [18F]FAPI-74 showed rapid clearance by the kidneys and high accumulation in the tumour and intestine 1 h after administration. [177Lu]FAPI-46 and [225Ac]FAPI-46 also showed rapid clearance by the kidneys and relatively high accumulation in the tumour at 3 h. Both [177Lu]FAPI-46 and [225Ac]FAPI-46 showed tumour-suppressive effects, with a mild decrease in body weight. The treatment effects of [177Lu]FAPI-46 were relatively slow but lasted longer than those of [225Ac]FAPI-46. CONCLUSION: This study suggested the possible application of FAPI radioligand therapy in FAP-expressing pancreatic cancer. Further evaluation is necessary to find the best radionuclide with shorter half-life, as well as the combination with therapies targeting tumour cells directly.
引用
- Liu Y, Watabe T, Kaneda-Nakashima K, et al. Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model. Eur J Nucl Med Mol Imaging. 2021. PMID: 34537893. doi:10.1007/s00259-021-05554-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。